Robert W. Baird Forecasts Strong Price Appreciation for Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its target price increased by stock analysts at Robert W. Baird from $46.00 to $48.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Robert W. Baird's price objective would indicate a potential upside of 16.17% from the company's previous close.

Several other research analysts have also issued reports on TWST. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Finally, Barclays dropped their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and an average target price of $51.78.

Twist Bioscience Stock Down 0.3 %

NASDAQ TWST traded down $0.11 during trading hours on Tuesday, hitting $41.32. 922,236 shares of the company were exchanged, compared to its average volume of 952,344. The stock has a market cap of $2.42 billion, a PE ratio of -10.74 and a beta of 1.78. Twist Bioscience has a 52 week low of $23.00 and a 52 week high of $60.90. The stock has a 50-day moving average price of $43.98 and a 200 day moving average price of $46.18.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 1,057 shares of the firm's stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the sale, the senior vice president now directly owns 121,013 shares in the company, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the sale, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the business. ProShare Advisors LLC boosted its position in shares of Twist Bioscience by 10.2% during the first quarter. ProShare Advisors LLC now owns 14,444 shares of the company's stock worth $496,000 after buying an additional 1,336 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Twist Bioscience by 14.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 18,649 shares of the company's stock worth $640,000 after buying an additional 2,410 shares in the last quarter. Edgestream Partners L.P. acquired a new position in Twist Bioscience during the 1st quarter worth approximately $242,000. American International Group Inc. raised its holdings in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company's stock valued at $978,000 after purchasing an additional 213 shares in the last quarter. Finally, PEAK6 Investments LLC lifted its position in shares of Twist Bioscience by 20.7% during the 1st quarter. PEAK6 Investments LLC now owns 14,000 shares of the company's stock worth $480,000 after purchasing an additional 2,400 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.